Investor Relations

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.

The attached document discloses the data of the transactions made in Ambu shares. 

Read the company announcement here, as well as the attached documentation.

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated personsrelated to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.

The attached document discloses the data of the transactions made in Ambu shares. 

Read the company announcement here, as well as the attached documentation.

Ambu has expanded its newly launched Ambu^® SureSight™ Connect video laryngoscopy solution with the introduction of five new blades designed specifically for paediatric patients.

Today, Ambu announces the launch of additional sizes of video laryngoscope blades for the new Ambu^® SureSight™ Connect video laryngoscopy solution.

Following the launch of the Ambu® SureSight™ Connect solution in February 2025, which included five blades of sizes traditionally used in adult patients, Ambu launches five additional blades aimed at paediatric patients. This increases the breadth of the Ambu® SureSight™ Connect offering to serve a wider patient group and ensure comprehensive care that meets the diverse needs of healthcare professionals and patients.

"With the introduction of the Ambu^® SureSight™ Connect, I have all the tools I need to care for the broad range of complex patients I see as a paediatric anaesthesiologist – from our tiniest neonates to our largest teenagers."

Christopher Ward, M.D.¹
Department of Anesthesiology and Critical Care Medicine, 
Children’s Hospital of Philadelphia, USA

A stronger airway visualization and pulmonology offering
In addition to the Ambu^® SureSight™ Connect video laryngoscope, Ambu’s airway visualization and pulmonology offering includes the company’s range of single-use bronchoscopes, rhinolaryngoscopes, as well as single- and double-lumen tubes with an integrated camera for one-lung ventilation procedures, in full integration with Ambu’s advanced digital software systems, Ambu^® aView™ 2 Advance and Ambu^® aBox™.

Ambu’s integrated airway visualization and pulmonology offering allows healthcare professionals to switch between solutions as needed. This aims to reduce task complexity, simplify workflow and improve efficiency, giving healthcare professionals more time to focus on patients, while maintaining high standards of patient safety.

Ambu will first engage in a controlled market release phase, collaborating with healthcare professionals at key hospitals in the USA and Great Britain to evaluate the new blades’ performance in clinical settings before engaging in a full launch later in 2025.

"With the addition of five new blades designed specifically for paediatric patients, we are significantly extending our Ambu^® SureSight™ Connect solution to our customers. This important advancement allows us to meet their needs with the most comprehensive portfolio in the industry, ensuring they can work more efficiently to deliver the highest standards of patient care. Furthermore, it solidifies Ambu’s strong leadership position in airway management and pulmonology, showcasing our continued commitment to customer-centric innovation."

Britt Meelby Jensen
Chief Executive Officer, Ambu


--------------------------

¹   Dr. Ward has not been compensated for his quote in this press release.
²   Ambu’s single-lumen tubes, Ambu^® VivaSight™ 2 SLT, are not commercially available in the USA.

Read the full press release here.